Exelixis enters crowded liver cancer field with Cabometyx, taking on Bayer, BMS and Merck

15th January 2019 Uncategorised 0

Exelixis’ fast-growing Cabometyx just added another FDA approval. It can now treat liver cancer patients if Bayer’s Nexavar is no longer helpful, putting it in a field that’s already crowded with Bayer’s Stivarga and some checkpoint inhibitor stars.

More: Exelixis enters crowded liver cancer field with Cabometyx, taking on Bayer, BMS and Merck
Source: fierce